GW Medical Technologies, LLC's New Blood Test For Alzheimer's Disease Seeks Future Test Candidates; Patients And Physicians Needed For Breakthrough Test
10/19/2005 5:10:15 PM
PHOENIX--(BUSINESS WIRE)--May 11, 2005--GW Medical Technologies LLC, the worldwide technology provider of the blood test for Alzheimer's disease (AD) known as the LymPro(TM) Test, announces a nationwide online registration of Alzheimer's patients, caregivers and physicians who want to become involved in upcoming clinical studies for this breakthrough diagnostic blood test for Alzheimer's disease.
Those individuals who are interested in participating in future clinical studies can register by going to the company Web site at www.GWmedtech.com. The online registration takes less than one minute to complete. As new clinical studies are launched, those who sign up as interested parties will be contacted first with complete study details and requirements. These studies will be part of the FDA Pre-market Approval (PMA) process for the LymPro Test, which the company is planning to submit to the FDA within the near future.